Article PDF
References
Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004 August 24 [Epub ahead of print].
Aledort LM. Adverse reactions related to rVIIa? (Letter). Am J Hematol 2001; 67: 213.
Pavese P, Bonadona A, Beaubien J, et al. FVIIa corrects the coagulopathy of fulminant hepatic failure but may be associated with thrombosis: a report of four cases. Can J Anesth 2005; 52: 26–9.
Abshire T, Kenet G. Recombinant factor VIIa: a review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004; 2: 899–909.
Levi M. Recombinant factor VIIa: a general hemostatic agent? Not yet. J Thromb Haemost 2004; 2: 1695–7.
Roberts HR. Recombinant factor VIIa: a general hemostatic agent? Yes. J Thromb Haemost 2004; 2: 1691–4.
Gabriel DA, Carr M, Roberts HR. Monitoring coagulation and the clinical effects of recombinant factor VIIa. Semin Hematol 2004; 41(Suppl 1): 20–4.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Roberts, H.R. Recombinant factor VIIa: how safeis the stuff?. Can J Anesth 52, 8–11 (2005). https://doi.org/10.1007/BF03018573
Issue Date:
DOI: https://doi.org/10.1007/BF03018573